Zoetis (NYSE:ZTS) Stock Bought Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros, Jr. disclosed buying Zoetis shares on June 16, with the trade valued between $1,001 and $15,000 in his Bank of America trust account.
• Zoetis recently reported quarterly EPS of $1.53, missing Wall Street estimates, while revenue of $2.26 billion also came in slightly below expectations. The company still raised/outlined FY 2026 guidance of 6.85 to 7.00 EPS.
• The stock has drawn mixed sentiment: analysts currently rate it Hold on average, and the company is also facing an investor lawsuit over securities-fraud allegations that may weigh on sentiment.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on July 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Zoetis stock on June 16th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of The Descartes Systems Group NASDAQ: DSGX on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Texas Roadhouse NASDAQ: TXRH on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Texas Capital Bancshares NASDAQ: TCBI on 6/30/2026.
• Sold $1,001 - $15,000 in shares of SoftBank Group OTCMKTS: SFTBF on 6/30/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 6/30/2026.
• Sold $1,001 - $15,000 in shares of RBC Bearings NYSE: RBC on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Microchip Technology NASDAQ: MCHP on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of HealthEquity NASDAQ: HQY on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 6/30/2026.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 6/30/2026.

Zoetis Price Performance

NYSE ZTS opened at $74.73 on Friday. Zoetis Inc. has a one year low of $71.47 and a one year high of $161.77. The stock has a 50-day moving average of $84.04 and a 200 day moving average of $109.40. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a market capitalization of $31.33 billion, a price-to-earnings ratio of 12.39, a PEG ratio of 1.17 and a beta of 0.75.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to analysts' expectations of $2.30 billion. During the same period in the previous year, the business earned $1.48 EPS. The business's revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis's dividend payout ratio (DPR) is 35.16%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. Weiss Ratings cut Zoetis from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, June 12th. Leerink Partners reiterated a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. UBS Group cut their target price on shares of Zoetis from $130.00 to $99.00 and set a "neutral" rating for the company in a research report on Friday, May 8th. Morgan Stanley reiterated an "overweight" rating and issued a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Finally, Barclays reduced their price objective on Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $126.92.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc NYSE: ZTS Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors...
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action...

Insider Activity

In other Zoetis news, Director Frank A. Damelio acquired 6,650 shares of the business's stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares of the company's stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. J. Stern & Co. LLP boosted its holdings in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. Norges Bank bought a new stake in Zoetis in the 4th quarter worth approximately $734,425,000. Vanguard Group Inc. boosted its position in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. purchased a new position in shares of Zoetis in the first quarter valued at $286,660,000. Finally, Nordea Investment Management AB raised its stake in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.